Mounjaro, manufactured by Eli Lilly and Co., is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar in adults with type 2 diabetes mellitus. Mounjaro received FDA approval in May of 2022.
Mounjaro is a glucagon-like peptide-1 (GLP-1) receptor agonist, like Ozempic, which is produced by Novo Nordisk. In addition, Mounjaro also activates glucose-dependent insulinotropic peptide (GIP), a hormone that helps release insulin after consumption.
Eli Lilly claims on the Mounjaro website that studies showed 3 out of 4 people reached an A1C under 7%, from an average starting at 7.9% to 8.6%.